Research
Engineering antibodies for therapeutic applications
Antibody effector functions
Publications
See website listing above for Google Scholar, Research Gate and LinkedIn profiles
Armour KL, Smith CS, Turner CP, Kirton CM, Wilkes AM, Hadley AG, Ghevaert C, Williamson LM, Clark MR. Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets. Eur J. Immunol. 2014 March; 44(3): 905-914
Ghevaert C, Herbert N, Hawkin L, Grehan N, Cookson P, Garner SF, Crisp-Hihn A, Lloyd-Evans P, Evans A, Balan K, Ouwehand WH, Armour KL, Clark MR, Williamson LM. Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood. 2013 July 18;122(3):313-320
Goh YS, Grant AJ, Restif O, McKinley TJ, Armour KL, Clark MR, Mastroeni P. Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology. 2011 May;133(1):74-83
Armour KL, Smith CS, Clark MR. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J Immunol Methods. 2010 Mar 31;354(1-2):20-33
Armour KL, Parry-Jones DR, Beharry N, Ballinger JR, Mushens R, Williams RK, Beatty C, Stanworth S, Lloyd-Evans P, Scott M, Clark MR, Peters AM, Williamson LM. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood. 2006 Apr 1;107(7):2619-26.
